RxDoctor Payments Data

William Coleman, MD

Neurology · Newburgh, INNPI 1811343676

Payments from drug & device makers

$17,934in general payments, 2019–2025

Across 513 payments — averaging $34.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$10K
  • AbbVie$3K
  • Teva Pharmaceuticals USA, Inc.$734
  • UCB, Inc.$503
  • Lundbeck LLC$286
  • Catalyst Pharmaceuticals, Inc.$271
  • plus $3K from 36 others

What the payments were for

  • Speaking & faculty fees$9,45053%
  • Food & beverage$8,37247%
  • Education$1111%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,934 in reported general payments places this provider in the 75th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$139,296
Medicare patients
99
Services billed
16,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant126$174,128
QuliptaAtogepant97$162,395
Emgality PenGalcanezumab-Gnlm197$149,867
Nurtec OdtRimegepant Sulfate73$103,852
TrudhesaDihydroergotamine Mesylate18$98,782
Aimovig AutoinjectorErenumab-Aooe112$83,159
ReyvowLasmiditan Succinate74$68,149
Ajovy AutoinjectorFremanezumab-Vfrm45$58,773
Emgality SyringeGalcanezumab-Gnlm23$30,919
ZavzpretZavegepant Hcl22$23,281
Ajovy SyringeFremanezumab-Vfrm17$13,240
Eletriptan HbrEletriptan Hydrobromide26$3,239
Sumatriptan Succinate131$2,801
Acetazolamide11$1,746
Gabapentin111$1,683

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$3,323$336,523223 claims
PfizerNurtec Odt, Zavzpret$10,246$127,13295 claims
Impel Pharmaceuticals Inc.Trudhesa$17$98,78218 claims
Lilly USA, LLCReyvow$174$68,14974 claims
Upsher-smith Laboratories LLCTopiramate$23$1,411103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 308 neurology providers in Indiana.

Other neurology in Newburgh

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →